Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

• Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026
  
  
• HAELO manuscript simultaneously published in the New England Journal of Medicine
  
  

CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. The presentation and publication can be accessed from the Scientific Publications and Presentations section of intelliatx.com.

As previously announced, HAELO met its primary endpoint with an 87% reduction (p<0.0001) in mean monthly attacks in the lonvo-z arm vs. the placebo arm during the efficacy evaluation period (weeks 5 to 28). In addition, 62% of patients in the lonvo-z arm were entirely attack free and therapy free for the six-month efficacy evaluation period, compared with 11% of patients in the placebo arm (p<0.0001), a key secondary endpoint. Today, Intellia reported data for the trial’s other key secondary endpoints:

Key Secondary Endpoint	Lonvo-z Arm (N=52)	Placebo Arm (N=28)
Monthly rate of attacks requiring on-demand treatment Weeks 5-28, mean (95% CI)	0.19 (0.10, 0.36)	1.79 (1.27, 2.54)
	89% reduction (79%, 94%), p<0.0001
Monthly rate of moderate/severe attacks Weeks 5-28, mean (95% CI)	0.11 (0.06, 0.23)	1.23 (0.84, 1.81)
	91% reduction (81%, 96%), p<0.0001
Change from baseline to Week 28 in AE-QoL total score, mean (95% CI)	-23.51 (-27.64, -19.38)	-6.47 (-12.26, -0.68)
	-17.04 improvement (-24.15, -9.93), p<0.0001

^{AE-QoL: Angioedema Quality of Life score, which is a validated, angioedema-specific patient-reported outcome measure with a lower score indicating improved quality of life. A 6-point reduction is considered to be a clinically important improvement in AE-QoL.}

Schreibe Deinen Kommentar